The sodium-glucose cotransporter 2 (SGLT2) is a glucose transporter primarily located in the proximal tubule of the kidney, where it reabsorbs glucose back into the bloodstream. SGLT2 inhibitors, which block SGLT2 function, are used to manage hyperglycemia in diabetes mellitus patients. Surprisingly, these inhibitors also have a secondary effect of lowering blood pressure independent of blood glucose levels. This review explores the role of SGLT2 in blood glucose and blood pressure regulation, the clinical significance of SGLT2 inhibitors in managing blood pressure in diabetic and nondiabetic individuals, and the potential mechanisms by which SGLT2 influences blood pressure control in the central nervous system. SGLT2 is found in various regions of the brain, including the nucleus tractus solitarius (nTS), which plays a crucial role in cardiorespiratory regulation. Studies have shown that SGLT2 inhibitors can reduce blood pressure through mechanisms such as osmotic diuresis, natriuresis, and modulation of the sympathetic nervous system. The review also discusses the neuroprotective effects of SGLT2 expression and the potential therapeutic applications of targeting SGLT2 in the brain for blood pressure regulation.The sodium-glucose cotransporter 2 (SGLT2) is a glucose transporter primarily located in the proximal tubule of the kidney, where it reabsorbs glucose back into the bloodstream. SGLT2 inhibitors, which block SGLT2 function, are used to manage hyperglycemia in diabetes mellitus patients. Surprisingly, these inhibitors also have a secondary effect of lowering blood pressure independent of blood glucose levels. This review explores the role of SGLT2 in blood glucose and blood pressure regulation, the clinical significance of SGLT2 inhibitors in managing blood pressure in diabetic and nondiabetic individuals, and the potential mechanisms by which SGLT2 influences blood pressure control in the central nervous system. SGLT2 is found in various regions of the brain, including the nucleus tractus solitarius (nTS), which plays a crucial role in cardiorespiratory regulation. Studies have shown that SGLT2 inhibitors can reduce blood pressure through mechanisms such as osmotic diuresis, natriuresis, and modulation of the sympathetic nervous system. The review also discusses the neuroprotective effects of SGLT2 expression and the potential therapeutic applications of targeting SGLT2 in the brain for blood pressure regulation.